A Randomized Phase III Study Comparing 5-FU; Leucovorin and Oxaliplatin Versus 5-FU; Leucovorin; Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers